Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Clinical trial NCT01843374 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT01843374

Sponsor

MedImmune LLC

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2013-05-17

Primary completion

2016-01-24

Enrollment

571

View on ClinicalTrials.gov